It's not a "highly subjective" conclusion that Xeriant has many many failures and abandoned definitive deals and JVs, and has racked up about $10M in debt, has no revenues, and no prospects for short term revenues, no $130M Nexboard and/or $120M additional Retacell products deal, not with zero-existing-revenues $5M-public-offering-seeking Next New Concept, Inc., or any other company, also having abandoned its Movychem obligations.
The evidence is quite clear that Xeriant, Inc. is an ongoing
going concern and unworthy of new retail investment as Xeriant's risk to reward is massively weighted as extremely high risk.
Too bad you're too pussy to even address these facts.
.